Browsing Tag
Datroway
7 posts
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.
Avacta FY25 puts AVCT on a clock: £16.9m cash, two Phase 1 reads, one shot
Avacta Group posts FY25 results with two clinical assets in trial, £16.9m cash, and AVA6103 data due in H2 2026 as AVCT trades near 52-week high.
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
Avacta Group (AIM: AVCT) delivers preCISION payload data that challenges Enhertu and Datroway tumor selectivity at Science Day 2026
Avacta is no longer pitching a platform. It is benchmarking preCISION directly against Enhertu and Datroway, and the tumor selectivity numbers matter.
TROPION-PanTumor03 trial reports breakthrough responses with DATROWAY and Rilvegostomig combo in bladder cancer
Discover how DATROWAY plus rilvegostomig is rivaling the EV-302 standard with high response rates in metastatic urothelial cancer.
Daiichi Sankyo (TSE: 4568) and AstraZeneca (NASDAQ: AZN) surge on Datroway’s historic first-line TNBC survival win
Find out how Datroway’s first-line TNBC survival win could rewrite chemotherapy-first playbooks and accelerate the ADC era in breast cancer—read the full analysis.
Datroway approved in US: A new era in metastatic breast cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan), a first-in-class…